The baseline characteristics of the study population were as follows:
proportion of men, 54.5%;
Caucasian origin, 53.2%;
mean age, 52.45 years;
mean body mass index (BMI), 31.45 kg/m2;
mean duration of diabetes, 9 years;
mean HbA1c, 9.77%.
The following baseline patient characteristics were considered.
The rate of hypertensive heart disease was 0%.
The rate of angina pectoris was 1.72%.
The rate of myocardial infarction was 2.15%.
The rate of heart failure was 0.43%.
The rate of cardiac dysrhythmia was 1.29%.
The rate of stroke was 0%.
The rate of peripheral vascular disease was 0.86%.
The rate of peripheral neuropathy was 23.2%.
The rates of foot ulcer and amputation were 0.43%.
The rates of microalbuminuria and gross proteinuria were 4%.
The rate of background diabetes retinopathy was 8.5%.
The rate of proliferative diabetic retinopathy was 0%.
The rate of blindness and low vision was 8.5%.
The rate of cataract was 4.3%.
The rate of macular oedema was 0%.
The proportion of patients taking angiotensin-converting enzyme inhibitors or angiotensin receptor blockers was 20.6%.
The proportion of patients taking statins was 17.8%.
The proportion of patients taking aspirin was 7.7%.
The rates of patients screened for retinopathy, renal disease and foot disease were 63.2%, 60% and 37.3%, respectively.
In terms of the effectiveness of treatment, the change from baseline in HbA1c was -2.79% with BIAsp 30/70 and -2.36% with glargine.
The change from baseline in BMI was +1.88 kg/m2 with BIAsp 30/70 and +1.22 kg/m2 with glargine.
The increase from baseline in total dose of insulin (in units per kg of body weight) was +0.82 with BIAsp 30/70 and +0.55 with glargine.
Transition probabilities were based on the published CORE Diabetes Model and were not reported.